What is claimed is:

1. A compound that is 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide or a pharmaceutically acceptable salt thereof.

2. The pharmaceutically acceptable salt of claim 1, wherein said salt is ahydrochloride salt of 4-(2,2-difluoro-benzo[1 ,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl )-amide.

3. The pharmaceutically acceptable salt of claim 2, wherein said hydrochloride salt is bis-hydrochloride.

4. Use of at least one of 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide and a pharmaceutically acceptable salt thereof in the treatment of disease modulated by FAAH activity.

5. Use of at least one of 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide and a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of disease modulated by FAAH activity.

6. A pharmaceutical composition comprising:
(a) a therapeutically effectiveamount of 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide or a pharmaceutically acceptable salt thereof; and
(b) a pharmaceutically acceptable excipient.

7. The pharmaceutical composition of claim 6 for use in the treatment of a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by FAAH activity.

8. The composition according to claim 7, wherein said disease, disorder or medical condition is selected from the group consisting of: anxiety, depression, pain, sleep disorders, eating disorders, inflammation, movement disorders, HIV wasting syndrome,

closed head injury, stroke, learning and memory disorders, Alzheimer's disease, epilepsy, Tourette's syndrome, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, cerebral vasospasm, glaucoma, irritable bowel syndrome, inflammatory bowel disease, immunosuppression, gastroesophageal reflux disease, paralytic ileus, secretory diarrhea, gastric ulcer, rheumatoid arthritis, unwanted pregnancy, hypertension, cancer, hepatitis, allergic airway disease, autoimmune diabetes, intractable pruritis, neuroinflammation, diabetes, metabolic syndrome, and osteoporosis.

9. The composition according to claim 7, wherein said disease, disorder or medical condition is pain or inflammation

10. The composition according to claim 7, wherein said disease, disorder or medical condition is anxiety, a sleep disorder, an eating disorder, or a movement disorder.

11. The composition according to claim 7, wherein said disease, disorder or medical condition is multiple sclerosis.

12. The composition according to claim 7, wherein said disease, disorder or medical condition is energy metabolism or bone homeostasis.

13. A method of synthesizing 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide using 2,2-difluorobenzo[1,3]dioxole-5-carbaldehyde and piperazine in a single step hydrogenation reaction.

What is claimed is:

1. A compound that is 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide or a pharmaceutically acceptable salt thereof.

2. The pharmaceutically acceptable salt of claim 1, wherein said salt is a hydrochloride salt of 4-(2,2-difluoro-benzo[1 ,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl )-amide.

3. The pharmaceutically acceptable salt of claim 2, wherein said hydrochloride salt is bis-hydrochloride.

4. At least one of 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide and a pharmaceutically acceptable salt thereof for use in the treatment of a disease selected from the group consisting of: anxiety, depression, pain, sleep disorders, eating disorders, inflammation, movement disorders, HIV wasting syndrome, closed head injury, stroke, learning and memory disorders, Alzheimer's disease, epilepsy, Tourette's syndrome, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, cerebral vasospasm, glaucoma, irritable bowel syndrome, inflammatory bowel disease, immunosuppression, gastroesophageal reflux disease, paralytic ileus, secretory diarrhea, gastric ulcer, rheumatoid arthritis, unwanted pregnancy, hypertension, cancer, hepatitis, allergic airway disease, autoimmune diabetes, intractable pruritis, neuroinflammation, diabetes, metabolic syndrome, and osteoporosis.

5. The use of at least one of 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide and a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease selected from the group consisting of: anxiety, depression, pain, sleep disorders, eating disorders, inflammation, movement disorders, HIV wasting syndrome, closed head injury, stroke, learning and memory disorders, Alzheimer's disease, epilepsy, Tourette's syndrome, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, cerebral vasospasm, glaucoma, irritable bowel syndrome,

inflammatory bowel disease, immunosuppression, gastroesophageal reflux disease, paralytic ileus, secretory diarrhea, gastric ulcer, rheumatoid arthritis, unwanted pregnancy, hypertension, cancer, hepatitis, allergic airway disease, autoimmune diabetes, intractable pruritis, neuroinflammation, diabetes, metabolic syndrome, and osteoporosis.

6. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide or a pharmaceutically acceptable salt thereof; and
(b) a pharmaceutically acceptable excipient.

7. The pharmaceutical composition of claim 6 for use in the treatment of a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by FAAH activity.

8. The composition according to claim 7, wherein said disease, disorder or medical condition is selected from the group consisting of: anxiety, depression, pain, sleep disorders, eating disorders, inflammation, movement disorders, HIV wasting syndrome, closed head injury, stroke, learning and memory disorders, Alzheimer's disease, epilepsy, Tourette's syndrome, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, cerebral vasospasm, glaucoma, irritable bowel syndrome, inflammatory bowel disease, immunosuppression, gastroesophageal reflux disease, paralytic ileus, secretory diarrhea, gastric ulcer, rheumatoid arthritis, unwanted pregnancy, hypertension, cancer, hepatitis, allergic airway disease, autoimmune diabetes, intractable pruritis, neuroinflammation, diabetes, metabolic syndrome, and osteoporosis.

9. The composition according to claim 7, wherein said disease, disorder or medical condition is pain or inflammation

10. The composition according to claim 7, wherein said disease, disorder or medical condition is anxiety, a sleep disorder, an eating disorder, or a movement disorder.

11. The composition according to claim 7, wherein said disease, disorder or medical condition is multiple sclerosis.

12. The composition according to claim 7, wherein said disease, disorder or medical condition is energy metabolism or bone homeostasis.

13. A method of synthesizing 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide using 2,2-difluorobenzo[1,3]dioxole-5-carbaldehyde and piperazine in a single step hydrogenation reaction.